Contrasting Neumora Therapeutics (NMRA) and Its Competitors

Neumora Therapeutics (NASDAQ:NMRA) is one of 296 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Neumora Therapeutics to related companies based on the strength of its dividends, risk, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares Neumora Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-73.63%	-68.97%
Neumora Therapeutics Competitors	-4,764.90%	-166.08%	-43.45%

Volatility & Risk

Neumora Therapeutics has a beta of 3.92, meaning that its share price is 292% more volatile than the S&P 500. Comparatively, Neumora Therapeutics’ competitors have a beta of 1.17, meaning that their average share price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Neumora Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	0	2	5	0	2.71
Neumora Therapeutics Competitors	1731	5064	13188	259	2.59

Neumora Therapeutics presently has a consensus price target of $21.67, suggesting a potential upside of 122.45%. As a group, “Biological products, except diagnostic” companies have a potential upside of 65.48%. Given Neumora Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Neumora Therapeutics is more favorable than its competitors.

Valuation & Earnings

This table compares Neumora Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neumora Therapeutics	N/A	-$235.93 million	-5.21
Neumora Therapeutics Competitors	$578.42 million	-$35.20 million	3.54

Neumora Therapeutics’ competitors have higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by insiders. Comparatively, 16.0% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neumora Therapeutics beats its competitors on 7 of the 13 factors compared.

About Neumora Therapeutics

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.